2022-04-212022-04-212006-08Ersoy, A. (2006). ''Current and future antihypertensive drugs in post-transplant hypertension and related patents''. Expert Opinion on Therapeutic Patents, 16(8), 1093-1106.1354-37761744-7674https://doi.org/10.1517/13543776.16.8.1093https://www.tandfonline.com/doi/full/10.1517/13543776.16.8.1093http://hdl.handle.net/11452/25974Hypertension is common in renal transplant recipients (RTR) and may contribute to the high incidence of morbidity and mortality from cardiovascular disease. Its treatment is an important factor necessary to ensure long-term patient and allograft survival. Although all anti hypertensive drugs are useful in RTRs, the most commonly used drugs are calcium-channel blockers and renin-angiotensin system inhibitors. This article briefly reviews traditional drugs together with new anti hypertensive drugs under development, focusing on their possible advantages in RTRs. In addition, many patents reporting chemical processes and pharmaceutical formulations of these drugs are also summarised.eninfo:eu-repo/semantics/closedAccessPharmacology & pharmacyKidney transplantationHypertensionAntihypertensive drugsAce-inhibitorRisk-assessmentBlood-pressureOxidative stressKidney-transplantationAngiotensin-IIGlycation end-productsConverting enzyme-inhibitionCalcium-channel blockersRenal-transplant recipientsArticle0002426002000042-s2.0-3374707145010931106168Chemistry, medicinalPharmacology & pharmacyKidney Transplantation; Transplant Recipients; Ambulatory Blood Pressure MonitoringVerapamilValsartanUnindexed drugTelmisartanSteroidQuinaprilPlaceboOlmesartanNitrendipineNifedipineManidipineLosartanLisinoprilIsradipineIrbesartanEprosartanEnalapril maleateDipeptidyl carboxypeptidase inhibitorDiltiazemCandesartan hexetil; cyclosporin ACandesartanCalcium channel blocking agentCalcineurin inhibitorBeta adrenergic receptor blocking agentAtenololAntihypertensive agentAngiotensin receptor antagonistAngiotensin 1 receptor antagonistAmlodipineSurvival timeReviewRenin angiotensin aldosterone systemRashPostoperative periodPatentNephrotoxicityKidney transplantationKidney graftHypertensionHyperkalemiaHumanGraft survivalGraft recipientDrug half lifeDrug formulationDrug designDisease exacerbationDiabetes mellitusCoughingClinical trialAngioneurotic edemaAnemiaAnaphylaxis